(Q35093647)

6 August 2017

1 reference

title

Efficacy and safety of HLA-B7/beta-2 microglobulin plasmid DNA/lipid complex (Allovectin-7) in patients with metastatic melanoma (English)

1 reference

6 August 2017

1 reference

Michael Bergen

1

1 reference

6 August 2017

Robert Chen

series ordinal

2

1 reference

6 August 2017

Rene Gonzalez

series ordinal

3

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

Expert Opinion on Biological Therapy

6 August 2017

published in

1 reference

6 August 2017

volume

3

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

377-384

1 reference

6 August 2017

cites work

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.377

Malignant melanoma: prevention, early detection, and treatment in the 21st century

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.377

Update on the incidence and mortality from melanoma in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.377

The suppressor-cell network in cancer (first of two parts).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.377

beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.377

Intensity of class I antigen expression on human tumour cell lines and its relevance to the efficiency of non-MHC-restricted killing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.377

A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.377

Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.377

Dendritic cells: On the move from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.377

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.377

Genetically modified tumour vaccines: an obstacle race to break host tolerance to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.377

A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.377

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.377

Cancer Gene Therapy Using Plasmid DNA: Pharmacokinetic Study of DNA Following Injection in Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.377

Tissue distribution of the cytofectin component of a plasmid-DNA/cationic lipid complex following intravenous administration in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.377

Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.377

Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.377

21 January 2018

Identifiers

DOI

10.1517/14712598.3.2.377

1 reference

6 August 2017

1 reference